Vera Therapeutics appoints Christopher Hite director

Vera Therapeutics reported that its board appointed Christopher Hite as a Class III director effective March 5, 2026, with his initial term running until the 2027 annual stockholders’ meeting.

Rhea-AI Filing Summary

Vera Therapeutics reported that its board appointed Christopher Hite as a Class III director effective March 5, 2026, with his initial term running until the 2027 annual stockholders’ meeting. His compensation follows the company’s non-employee director policy.

On joining the board, Hite received a nonstatutory stock option to purchase 24,937 shares of Class A common stock at an exercise price of $38.85 per share. The option vests monthly over three years, subject to his continued service. He will also receive an annual cash retainer of $45,000, pro-rated for 2026.

Beginning with the 2027 annual meeting, Hite will be eligible each year for an option to buy up to the lesser of 18,000 shares or the number of shares with a grant date fair value not above $400,000, vesting by the next annual meeting or one year from grant. He will sign the company’s standard indemnification agreement, and the company notes there were no special arrangements or related-person transactions tied to his selection.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Vera Therapeutics (VERA) announce about its board of directors?

Vera Therapeutics announced that Christopher Hite has been appointed as a Class III director effective March 5, 2026. His initial term runs until the 2027 annual stockholders’ meeting, and his compensation follows the company’s non-employee director compensation policy.

What stock option grant did Christopher Hite receive from Vera Therapeutics (VERA)?

Christopher Hite received a nonstatutory stock option to purchase 24,937 shares of Vera Therapeutics’ Class A common stock at an exercise price of $38.85 per share. The option vests monthly over three years, conditioned on his continued service on the board.

What cash compensation will Christopher Hite receive as a Vera Therapeutics (VERA) director?

Under the company’s director compensation policy, Christopher Hite will receive an annual cash retainer of $45,000 for his board service. This amount will be pro-rated for 2026 based on his March 5, 2026 appointment date and ongoing board service.

What future annual equity awards may Christopher Hite receive from Vera Therapeutics (VERA)?

Starting with the 2027 annual meeting, Christopher Hite will be eligible for an annual option to buy the lesser of 18,000 shares or a number of shares with a grant date fair value not exceeding $400,000, vesting by the next annual meeting or one year from grant.

Were there any related-party transactions disclosed involving Christopher Hite and Vera Therapeutics (VERA)?

The company stated there are no related person transactions between Christopher Hite and Vera Therapeutics that require disclosure under Item 404(a) of Regulation S-K. It also noted there were no arrangements or understandings with others regarding his selection as a director.

Will Christopher Hite receive indemnification from Vera Therapeutics (VERA)?

Christopher Hite will enter into Vera Therapeutics’ standard form of indemnification agreement. This agreement is designed to protect directors in connection with their board service, consistent with the protections the company provides to its other non-employee directors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/09/2026 - 05:01 PM Learn about SEC filing dates

0001831828false00018318282026-03-052026-03-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 05, 2026

Vera Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-40407	81-2744449
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
2000 Sierra Point Parkway, Suite 1200
Brisbane, California				94005
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (650) 770-0077

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A common stock, $0.001 par value per share		VERA		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 5, 2026, the board of directors (the “Board”) of Vera Therapeutics, Inc. (the “Company”) appointed Christopher Hite to the Board, effective immediately. Mr. Hite will serve as a Class III Director, with an initial term expiring at the Company’s 2027 Annual Meeting of Stockholders.

Contingent upon and effective as of Mr. Hite’s appointment to the Board, Mr. Hite was automatically granted a nonstatutory stock option award (the “Option Grant”) to purchase 24,937 shares of the Company’s Class A common stock (“Common Stock”) with a per-share exercise price of $38.85, pursuant to the Company’s Amended and Restated Non-Employee Director Compensation Policy (as it may be amended from time to time, the “Policy”). The Option Grant will vest monthly over a three-year period, subject to Mr. Hite’s continuous service as of each such vesting date, and is otherwise subject to the same terms set forth in the Policy for initial grants to new directors. In addition, in accordance with the Policy, Mr. Hite will also receive an annual cash retainer of $45,000 for his service on the Board which will be pro-rated for 2026. Pursuant to the Policy, commencing with the Company’s 2027 Annual Meeting of Stockholders, Mr. Hite will be eligible to receive an annual option grant to purchase the lesser of (i) 18,000 shares of Common Stock and (ii) the maximum number of shares of Common Stock that would result in the option having a grant date fair value of not more than $400,000, subject to his continuous service as of such date. The shares subject to each such option grant would vest on the earlier of (a) the first anniversary of the date of grant and (b) the date of the Company’s next annual meeting of stockholders, subject to Mr. Hite’s continuous service as of each such date.

Mr. Hite will enter into the Company’s standard form of indemnification agreement. There were no arrangements or understandings between Mr. Hite and any other persons pursuant to which he was selected as a director, and there are no related person transactions within the meaning of Item 404(a) of Regulation S-K promulgated by the U.S. Securities and Exchange Commission between Mr. Hite and the Company required to be disclosed herein.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Vera Therapeutics, Inc.
Date:	March 9, 2026	By:	/s/ Sean Grant
			Sean Grant Chief Financial Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 24.4 KB